SCHEMBL2148453

SCHEMBL2148453

CCCCCCCCCCCC(CCCCCCCCCC)CC(CC(O)CO)OC(CC(O)CO)CC(CCCCCCCCCC)CCCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
USP2 O75604 1/20 0.43
CYP2D6 P10635 2/20 0.41
KDM4E B2RXH2 2/20 0.41
SPHK1 Q9NYA1 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CETP P11597 1/20 0.41
HTT P42858 1/20 0.41
UBE2N P61088 1/20 0.41
DUSP3 P51452 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627692 0.89 USP2 (0.46) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL9073956 0.87 USP2 (0.47) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL17237494 0.87 USP2 (0.47) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL17237503 0.87 USP2 (0.47) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL17237492 0.87 USP2 (0.47) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL11656416 0.85 USP2 (0.44) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL24688360 0.85 LMNA (0.64) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL19788324 0.85 LMNA (0.64) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL19287004 0.85 LMNA (0.64) LMNAUSP2CYP2D6KDM4ESPHK1
SCHEMBL24919805 0.85 LMNA (0.64) LMNAUSP2CYP2D6KDM4ESPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723309-B1 COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND TWO PARTICULAR DISTINCT SILICONE OILS OREAL (FR) 2018-10-17 EP claimed
EP-2512428-B1 COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND A PARTICULAR OIL L'ORÉAL (FR) 2017-04-05 EP claimed
EP-2512427-B1 COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND A PARTICULAR ADDITIONAL INGREDIENT OREAL (FR) 2013-11-06 EP claimed
EP-2140858-A1 Cosmetic or dermatological composition comprising a compound capable of creating hydrogen bonds, and cosmetic treatment method L'Oréal (FR) 2010-01-06 EP claimed
US-20220023189-A1 Personal Care Compositions COLGATE-PALMOLIVE COMPANY (US) 2022-01-27 US disclosed
US-20220000755-A1 Personal Care Compositions COLGATE-PALMOLIVE COMPANY (US) 2022-01-06 US disclosed
EP-3873621-A1 PERSONAL CARE COMPOSITIONS Colgate-Palmolive Company (US) 2021-09-08 EP disclosed
EP-3873412-A1 PERSONAL CARE COMPOSITIONS Colgate-Palmolive Company (US) 2021-09-08 EP disclosed
US-20210052478-A1 PERSONAL CARE COMPOSITIONS ALTUS LABS, LLC 2021-02-25 US disclosed
WO-2020117239-A1 PERSONAL CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2020-06-11 WO disclosed
WO-2020117238-A1 PERSONAL CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2020-06-11 WO disclosed
WO-2019136351-A1 PERSONAL CARE COMPOSITIONS ALTUS LABS, LLC (US) 2019-07-11 WO disclosed
US-20100111884-A1 UV ABSORBER FORMULATIONS CIBA CORPORATION (US) 2010-05-06 US disclosed
EP-2140858-A1 Cosmetic or dermatological composition comprising a compound capable of creating hydrogen bonds, and cosmetic treatment method L'Oréal (FR) 2010-01-06 EP disclosed
WO-2009024293-A2 STRUCTURED COSMETIC PREPARATION HAVING SKIN-MOISTURISING PROPERTIES SCHWAN-STABILO COSMETICS GMBH & CO. KG (DE) 2009-02-26 WO disclosed
US-20090047313-A1 PREPARATION HAVING SKIN-MOISTURIZING PROPERTIES SCHWAN-STABILO COSMETICS GMBH & CO. KG (DE) 2009-02-19 US disclosed
EP-1408912-B1 TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS DOW CORNING (US) 2007-03-07 EP disclosed
EP-1408912-A2 TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS Dow Corning Corporation (US) 2004-04-21 EP disclosed
WO-2003009819-A2 TEMPERATURE INSENSITIVE ONE-PHASE MICROEMULSIONS DOW CORNING CORPORATION (US) 2003-02-06 WO disclosed
US-6498197-B1 Temperature insensitive one-phase microemulsions DOW CORNING CORPORATION 2002-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111884-A1 UV ABSORBER FORMULATIONS C1R, C1S, C9 LMNA 1485/4885USP2 1087/4885CYP2D6 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.